- Home
- SGMT vs DHF Comparison
SGMT vs DHF Comparison
Compare SGMT & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SGMT | DHF |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 170.9M |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | SGMT | DHF |
|---|---|---|
| Price | $10.84 | $2.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $26.13 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 294.4K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.50 | $2.32 |
| 52 Week High | $11.24 | $2.63 |
Technical Indicators
Market Signals| Indicator | SGMT | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 46.20 |
| Support Level | $6.60 | $2.32 |
| Resistance Level | $11.15 | $2.40 |
| Average True Range (ATR) | 0.51 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 70.54 | 33.33 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.